PROPHYLACTIC USE OF EMOLLIENTS IN CHILDREN WITH ATOPIC DERMATITIS AND POLLEN SENSIBILIZATION DURING THE FLOWERING SEASON OF VARIOUS PLANTS: A SINGLE CENTER, SIMPLE, OPEN, PROSPECTIVE COMPARATIVE STUDY
Authors:   National Research Center Institute of Immunology of the Russian Federal Biomedical Agency, Moscow, Russia, Litovkina A.O. ,   Department of Immunology of the School of Medicine of the Patrice Émery Lumumba People’s Friendship University of Russia, Moscow, Russia, Smolnikov E.V. ,   National Research Center Institute of Immunology of the Russian Federal Biomedical Agency, Moscow, Russia,   Department of Immunology of the School of Medicine of the Patrice Émery Lumumba People’s Friendship University of Russia, Moscow, Russia,   National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow, Russia, Elisyutina O.G. ,   National Research Center Institute of Immunology of the Russian Federal Biomedical Agency, Moscow, Russia,   Department of Immunology of the School of Medicine of the Patrice Émery Lumumba People’s Friendship University of Russia, Moscow, Russia, Fedenko E.S. ,   National Research Center Institute of Immunology of the Russian Federal Biomedical Agency, Moscow, Russia
Published: March 2023

Penetration of pollen allergens through the damaged skin barrier in patients with atopic dermatitis (AD) can lead to a worsening of the severity of the disease in sensibilized patients during the flowering season, however, the preventive effect of agents that restore the structure of the epidermal barrier has not been studied enough as yet. The purpose of this research was to study the clinical efficacy and safety of the La Roche-Posay Lipikar Syndet AP+ and Lipikar AP+M cosmetic products for the prevention of AD exacerbations in children during the flowering season. Materials and methods used: a single-center prospective experimental randomized comparative open study was conducted in Apr. 22-Jul. 11, 2022. The study included 19 children aged 6 to 15 y/o with AD sensibilized to pollen allergens. The two groups were formed: patients in the main group used Lipikar for 28 days and received standard AD therapy during the flowering period; patients in the control group received the standard AD therapy only. The severity of AD was evaluated with the SCORAD as well as the quality of life, pruritus intensity and corneometry were assessed during each of the three visits to pediatric allergologists. Changes in SCORAD were considered the primary endpoint of the research. Results: a statistically significant decrease in SCORAD were revealed by the 14th day of the study (p=0.007) in the main group; whilst at the same time there were no statistically significant decrease in SCORAD in the control group. It was also found that the quality of life improved statistically significantly by the 28th day of the study (p=0.001) in patients of the main group when evaluated the secondary endpoints of the study. The pruritus intensity decreased statistically significantly (p=0.002) by the 14th day of the study; the skin hydration increased (p=0.001) as well (compared to the control group). Conclusion: the use of the Lipikar Syndet AP+ and Lipikar AP+M in children in the complex therapy of AD during the flowering season of causally significant allergens statistically significantly reduced the severity of AD, reduced the pruritus intensity, improved skin hydration and quality of life.